 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 1234» |
- | Jetrea (ocriplasmin) / Oxurion
Journal: Current treatment strategies for vitreomacular traction and macular holes: a survey of retinal specialists in Germany (Pubmed Central) - Sep 26, 2024
The results presented provide an overview of the consensus and controversies in the current treatment options for VMT and MF. With the help of a
- || Jetrea (ocriplasmin) / Oxurion
Review, Journal: Scoping review of non-surgical treatment options for macular holes. (Pubmed Central) - Sep 7, 2024
Treatments included laser therapy, carbonic anhydrase inhibitors (CAIs), nonsteroidal antiinflammatory drugs (NSAIDs), steroids (topical, subtenons, peribulbar, intravitreal), intravitreal gas, anti-vascular endothelial growth factors and ocriplasmin injections...Although non-surgical MH management approaches show potential for conservative therapy, evidence is limited to support routine use. Stage 1 and traumatic MH may benefit from a short period of observation but the gold standard approach for full-thickness MH remains to be vitrectomy with ILM peel.
- || Jetrea (ocriplasmin) / Oxurion
Review, Journal: Vitreomacular traction: diagnostics, natural course, treatment decision and guideline recommendations (Pubmed Central) - Jun 17, 2024
In addition to pars plana vitrectomy, alternative treatment options, such as intravitreal injection of ocriplasmin and pneumatic vitreolysis are discussed for vitreomacular traction with an associated macular hole; however, ocriplasmin is no longer available in Germany...Pneumatic vitreolysis is controversially discussed due to the increased risk of retinal tears. In one of the current S1
- || Jetrea (ocriplasmin) / Oxurion
Review, Journal: Macular hole: Differential diagnosis, treatment options and new guideline recommendations (Pubmed Central) - Jun 17, 2024
For FTMH associated with vitreomacular traction, alternative treatment options in addition to vitrectomy include intravitreal ocriplasmin injection and pneumatic vitreolysis. The current clinical guidelines of the German ophthalmological societies summarize the evidence-based recommendations for diagnosis and treatment of FTMH.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Effect Of Intravitreal Perfluoro Propane (C3f8) In The Management Of Symptomatic Vitreomacular Traction. (Pubmed Central) - Mar 1, 2024
The current clinical guidelines of the German ophthalmological societies summarize the evidence-based recommendations for diagnosis and treatment of FTMH. Intravitreal C3F8 is a cheaper and safer option for the treatment of vitreomacular traction as compared to pars plana vitrectomy or Ocriplasmin.
- | Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
Journal, Gene Signature, Immune cell: Identification of novel gene signatures and immune cell infiltration in intervertebral disc degeneration using bioinformatics analysis. (Pubmed Central) - Jul 31, 2023
Our data indicated that the 20 hub genes and immune cell infiltration were involved in the pathological process of IDD. In addition, the PDGFRA and two potential drugs were found to be significant in IDD development.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Macular hole Delphi consensus statement (MHOST). (Pubmed Central) - Jul 26, 2023
This Delphi study provides valuable information about the consensus/disagreement on different scenarios encountered during FTMH and LMH management as a guide tosurgical decision-making. High rate of disagreement and/or variable approaches still exist for treating such relatively common conditions.
- | Jetrea (ocriplasmin) / Oxurion
0,3 cc intravitreal C3F8 injection (pneumatic vitreolysis). Another alternative is ocriplasmin injection. (Twitter) - Jul 9, 2023
- | Biomarker, Journal: Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis. (Pubmed Central) - Mar 31, 2023
On the other hand, miR-940 which targets SERPINH1 could be used as a potential biomarker of CRC. More ever, Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, Bevacizumab, Ocriplasmin , and Collagenase clostridium histolyticum were introduced as therapeutic agents for CRC which their therapeutic potential should be evaluated experimentally.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Synthesis and structural characterization of new macrocyclic plasmin inhibitors. (Pubmed Central) - Mar 16, 2023
For the first time, four crystal structures of these macrocyclic inhibitors could be determined in complex with a Ser195Ala microplasmin mutant...This binding mode is incompatible with other trypsin-like serine proteases containing a sterically demanding 99-hairpin loop. The crystal structures obtained experimentally explain the excellent selectivity of this inhibitor type as previously hypothesized.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Identification of the Potential Molecular Mechanism of TGFBI Gene in Persistent Atrial Fibrillation. (Pubmed Central) - Nov 19, 2022
We used microdataset to identify the potential functions and mechanisms of the TGFBI and its coexpression genes in AF patients. Our findings suggest that CXCL12, C3, FN1, COL1A2, ACTB, VCAM1, and MMP2 may be the hub genes.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Idiopathic Vitreomacular Traction Managed with Initial Observation: Clinical Course and Outcomes. (Pubmed Central) - Oct 6, 2022
This study demonstrates the generally stable clinical course of VMT when managed initially by observation. Stable VMT grade was the most frequent outcome, and eyes with grade 1 VMT were more likely to undergo spontaneous release than eyes with grade 2 or 3.
- | Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo, TG 100-115 / Sanofi
Journal: Identification of the circRNA-miRNA-mRNA regulatory network in osteoarthritis using bioinformatics analysis. (Pubmed Central) - Oct 4, 2022
Finally, three chemicals (noscapine, diazepam, and TG100-115) based on CMap analysis and two drugs (collagenase Clostridium histolyticum and ocriplasmin) based on DGIdb were discovered as potential treatment options for OA. This study presents novel perspectives on the pathogenesis and treatment of OA based on circRNA-related competitive endogenous RNA regulatory networks.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Journal: Combined Pneumatic and Enzymatic Vitreolysis for Severe Cases of Vitreomacular Traction. (Pubmed Central) - Aug 27, 2022
This study presents novel perspectives on the pathogenesis and treatment of OA based on circRNA-related competitive endogenous RNA regulatory networks. Sequential, combined pneumatic and enzymatic vitreolysis resulted in VMT release in all 5 cases (4 cases by 28 days) and may be a potentially useful alternative to surgical intervention for refractory VMT cases.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model. (Pubmed Central) - Jul 26, 2022
Sequential, combined pneumatic and enzymatic vitreolysis resulted in VMT release in all 5 cases (4 cases by 28 days) and may be a potentially useful alternative to surgical intervention for refractory VMT cases. The developed multivariable model using 'horizontal VMT diameter' and 'age' is a valid tool for prediction of VMT resolution upon IVO treatment.
- | Jetrea (ocriplasmin) / Oxurion
Retrospective data, Review, Journal: Internal limiting membrane peeling in macular hole surgery. (Pubmed Central) - Jul 13, 2022
ILM abrasion technique and Ocriplasmin may eliminate the need of ILM peeling in selected cases, but they have their own limitations. We here discuss the role of ILM in the pathogenesis of macular hole, the benefits and adverse effects of ILM peeling, and the various modifications of the procedure, to then explore the alternatives.
- | Biomarker, Journal, Gene Signature: Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. (Pubmed Central) - Jul 2, 2022
The gene signature we identified in this study carries high potential as a predictive tool for poor prognosis in gastric cancer patients. Elucidating the mechanisms by which the signature genes contribute to poor patient outcomes can lead to the discovery of more potent molecular-targeted agents and increase the therapeutic success in gastric cancer.
- || Jetrea (ocriplasmin) / Oxurion
Retrospective data, Review, Journal: Ocriplasmin for Treatment of Vitreomacular Traction and Macular Hole A Systematic Literature Review and Individual Participant Data Meta-Analysis of Randomized, Controlled, Double-Masked Trials. (Pubmed Central) - May 29, 2022
Ocriplasmin promotes VMAR and MH closure. Transient visual phenomena are not uncommon.
- Jetrea (ocriplasmin) / Oxurion
Closure of Macular Holes With Topical Therapy and Why The Hydration Theory of Macular Hole Formation May Be Inaccurate (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_183;
This is especially true for small, early onset holes with minimal or no edema. There was no apparent deleterious effect of a 1-3 month delay while treating with eye drops as surgery still had a very high success rate.
- Jetrea (ocriplasmin) / Oxurion
Closure of Macular Holes With Topical Therapy and Why The Hydration Theory of Macular Hole Formation May Be Inaccurate ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_4527;
This is especially true for small, early onset holes with minimal or no edema. There was no apparent deleterious effect of a 1-3 month delay while treating with eye drops as surgery still had a very high success rate.
- || Jetrea (ocriplasmin) / Oxurion
Biomarker, Clinical, Journal, Tumor microenvironment: Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs. (Pubmed Central) - Apr 5, 2022
These results suggest that fibrinolytic cotherapy might help improve the therapeutic efficacy of anticancer nanomedicines. Thus, microplasmin-based fibrinolytic nanocages are promising candidates for this strategy due to their hemostatic safety and ability to home in on the tumor.
- || Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
Clinical, Journal: Gene Expression Profiling Analysis to Identify Key Genes and Underlying Mechanisms in Meniscus of Osteoarthritis Patients. (Pubmed Central) - Mar 23, 2022
In conclusion, we determined the underlying key genes, miRNAs, and circRNAs for OA, predicted potentially effective drugs, and identified the most meaningful biomarkers for the disease. Our findings may provide insight into the pathological mechanism of OA and guide future research.
- | Jetrea (ocriplasmin) / Oxurion
Journal: The Effect of Intravitreal Ocriplasmin on Hue Discrimination. (Pubmed Central) - Mar 23, 2022
Ocriplasmin may alter hue discrimination, but larger studies are required to provide sufficient power to detect or exclude a statistically significant effect. Longer follow-up is needed to determine the duration of any effect.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Resolution of outer retinal abnormalities in eyes with vitreomacular traction without macular hole in the OASIS trial. (Pubmed Central) - Mar 16, 2022
Release of VMT is usually associated with outer retinal recovery and an associated improvement in visual acuity. ELM recovery typically precedes EZ recovery and SRF resolution following VMT release.
- || Jetrea (ocriplasmin) / Oxurion
Biomarker, Retrospective data, Review: Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis. (Pubmed Central) - Feb 1, 2022
Evidence from included studies suggests that ocriplasmin is a suitable and safe approach for treating sVMA. ERM and MH status are important factors when considering ocriplasmin treatment.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Engineering of Ocriplasmin Variants by Bioinformatics Methods for the Reduction of Proteolytic and Autolytic Activities. (Pubmed Central) - Jan 27, 2022
Simulation analyses, consisting of the root-mean-square deviation, the root-mean-square fluctuation, and the center-of-mass average distance showed a higher affinity of the substrate for the wild type than for the mutant variants. The mutational analysis of ocriplasmin revealed that A59T and K156E mutagenesis could be used for the development of a new variant with higher therapeutic efficacy.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Retrospective data, Journal: Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics. (Pubmed Central) - Jan 27, 2022
However, the results of VMT release prediction in eyes with FTMHs accompanied by VMT matched the prediction of VMT release in eyes with VMT only when using the previously published formula. All in all, predictors for calculating the individual probability of VMT resolution on the one hand and FTMH closure on the other hand are different suggesting diverse pathophysiological mechanisms.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Journal: The efficacy and safety of ocriplasmin for patients with vitreous macular traction. (Pubmed Central) - Jan 18, 2022
Ocriplasmin is an effective, reliable and relatively safe intervention for the treatment of VMT. The most suitable candidates were patients younger than 65 years old, with smaller adhesion size (<1500 μm), phakic eyes, with MH and SRF, while without ERM.
- | Jetrea (ocriplasmin) / Oxurion
Biomarker, Journal: A revised predictive biomarker for ocriplasmin therapy in vitreomacular traction disorders. (Pubmed Central) - Jan 15, 2022
The most suitable candidates were patients younger than 65 years old, with smaller adhesion size (<1500 μm), phakic eyes, with MH and SRF, while without ERM. The threshold value of the VMT diameter for ocriplasmin therapy could be statistically defined as 480 µm and may thus be a new quantitative biomarker to predict treatment success.
- | risperidone / Generic mfg., pravastatin / Generic mfg., ritonavir / Generic mfg.
Journal: Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. (Pubmed Central) - Jan 14, 2022
Furthermore, nine potential therapeutic drugs (dasatinib, ocriplasmin, risperidone, gemfibrozil, ritonavir, fluvastatin, pravastatin, warfarin, atorvastatin) that target the key genes were also screened and selected. To conclude the key genes discovered (Lep, ApoE, Fyn, and FN1), as well as 9 candidate drugs, could be used as therapeutic targets in treating obesity.
- || Jetrea (ocriplasmin) / Oxurion
Retrospective data, Review, Journal, Real-world evidence: Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials. (Pubmed Central) - Jan 6, 2022
Lower ERM prevalence in RWS was the single significant explanatory variable for this difference. Conclusions on ocriplasmin safety in RWS are limited due to inconsistent reporting.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis. (Pubmed Central) - Nov 21, 2021
The anatomical result after one surgical intervention seems acceptable, but the final visual outcome remains rather poor, because of the underlying macular disease. In our population, injection with DEX is associated with higher IVARD rate, presence and development of PVR, and recurrent RRD in comparison with anti-VEGF agents.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Visual functional changes after ocriplasmin injection for vitreomacular traction: A microperimetric analysis. (Pubmed Central) - Oct 29, 2021
Microperimetry confirms an early and reversible functional impairment after ocriplasmin injection regardless VMT resolution. If a greater decrease in function could occur in the eyes without VMT resolution, a better functional recovery could occur in the event of VMT resolution.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Journal: OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study. (Pubmed Central) - Sep 16, 2021
The INJECT study showed that ocriplasmin is effective in a clinical setting in patients with VMT, with or without MH. No new safety signals were identified from this large and surgeon-selected patient group, although the significant limitations of the study design without an image reading center and scheduled study visit timings should be noted.
- | Jetrea (ocriplasmin) / Oxurion
Journal: Assessment of E. coli Expression System for Overexpression of Active Recombinant Ocriplasmin. (Pubmed Central) - Sep 14, 2021
The results of this study indicated that E. coli could be used for high level expression of ocriplasmin. Although the recombinant protein was expressed as inclusion body, the stepwise refolding leads to the biologically active proteins.
- || Jetrea (ocriplasmin) / Oxurion
P1 data, Journal: Phase I trial on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion. (Pubmed Central) - Sep 8, 2021
Robot-assisted retinal vein cannulation is feasible and safe. Local intravenous infusion with Ocriplasmin led to an improved retinal circulation.
- || Jetrea (ocriplasmin) / Oxurion
Retrospective data, Review, Journal: The effectiveness of ocriplasmin versus surgery for the treatment of macular holes: A systematic review and meta-analysis. (Pubmed Central) - Aug 21, 2021
A significant improvement in visual acuity of patients was seen after both treatments. More good quality randomized controlled trials are required to make strong conclusions.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Retrospective data: Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study). (Pubmed Central) - Jul 28, 2021
It is hypothesized that the status of the EZ at baseline is a contributing, ocriplasmin independent modulator of subsequent EZ changes after ocriplasmin. Prospective analyses which include a sham control group would be required to test this hypothesis.
- | Jetrea (ocriplasmin) / Oxurion
Retrospective data, Journal: EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS. (Pubmed Central) - Jul 18, 2021
Prospective analyses which include a sham control group would be required to test this hypothesis. In this retrospective analysis, the treatment with ocriplasmin showed a resolution of VMT in 7 of 10 patients (70.0%) after a follow-up period of 8 weeks.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Retrospective data, Journal: Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial. (Pubmed Central) - Jul 13, 2021
P3
The purpose of this study is to report on the frequency, severity, location and time course of ellipsoid zone (EZ) alterations in ocriplasmin-treated and sham control eyes in the OASIS study...The EZ abnormalities were apparent by week 1, persisted at month 1, and appeared to resolve in the majority of cases by month 3. NCT01429441.
- || Jetrea (ocriplasmin) / Oxurion
Clinical, Journal: PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. (Pubmed Central) - Jul 2, 2021
NCT01429441. A larger percentage of patients with symptomatic vitreomacular adhesion/vitreomacular traction reported clinically meaningful improvements in self-assessed visual function with ocriplasmin than sham.
- ||| Jetrea (ocriplasmin) / Oxurion
P3 data, Journal: BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS. (Pubmed Central) - Jun 22, 2021
A larger percentage of patients with symptomatic vitreomacular adhesion/vitreomacular traction reported clinically meaningful improvements in self-assessed visual function with ocriplasmin than sham. Vitreomacular traction is more likely to progress to FTMH when associated with subretinal fluid, but when associated with intraretinal changes (such as schisis), vitreomacular traction appears more likely to progress to a LH after a single intravitreal injection of ocriplasmin or saline.
- || Jetrea (ocriplasmin) / Oxurion
Review, Journal: Glucose -regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers and neurological disorders. (Pubmed Central) - Jun 5, 2021
M*), plasminogen kringle 5 (K5), microplasminogen, the voltage-dependent anion channel (VDAC), tissue factor (TF) and the prostate apoptosis response-4 protein (Par-4). In this review, we discuss the mechanisms involved in the translocation of GRP78 from the ER to the cell surface, and the role of secreted GRP78 and its autoantibodies in cancer and neurological disorders.
- Jetrea (ocriplasmin) / Oxurion
[VIRTUAL] Integrative ‘omics approach identifies common drugable BAP1-dependencies between Malignant Pleural Mesothelioma and Uveal Melanoma () - May 30, 2021 - Abstract #EACR2021EACR_349;
Conclusion A function-driven approach has identified novel BAP1-dependent adaptations in UM, by exploiting multi-omics data from an isogenic BAP1-mutated MPM model and correlating these with UM transcriptomic data. This may allow selection of effective drugs for BAP1 -mutant patients who are likely to develop mUM; UM cell line viability will initially be tested in response to drugs targeting FN1 (Ocriplasmin) and ATP1B1 (Digitoxin).
- Jetrea (ocriplasmin) / Oxurion
[VIRTUAL] Integrative ‘omics approach identifies common drugable BAP1-dependencies between Malignant Pleural Mesothelioma and Uveal Melanoma () - May 30, 2021 - Abstract #EACR2021EACR_348;
Conclusion A function-driven approach has identified novel BAP1-dependent adaptations in UM, by exploiting multi-omics data from an isogenic BAP1-mutated MPM model and correlating these with UM transcriptomic data. This may allow selection of effective drugs for BAP1 -mutant patients who are likely to develop mUM; UM cell line viability will initially be tested in response to drugs targeting FN1 (Ocriplasmin) and ATP1B1 (Digitoxin).
- Jetrea (ocriplasmin) / Oxurion
[VIRTUAL] Integrative ‘omics approach identifies common drugable BAP1-dependencies between Malignant Pleural Mesothelioma and Uveal Melanoma () - May 30, 2021 - Abstract #EACR2021EACR_347;
Conclusion A function-driven approach has identified novel BAP1-dependent adaptations in UM, by exploiting multi-omics data from an isogenic BAP1-mutated MPM model and correlating these with UM transcriptomic data. This may allow selection of effective drugs for BAP1 -mutant patients who are likely to develop mUM; UM cell line viability will initially be tested in response to drugs targeting FN1 (Ocriplasmin) and ATP1B1 (Digitoxin).
- Jetrea (ocriplasmin) / Oxurion
[VIRTUAL] Integrative ‘omics approach identifies common drugable BAP1-dependencies between Malignant Pleural Mesothelioma and Uveal Melanoma () - May 30, 2021 - Abstract #EACR2021EACR_346;
Conclusion A function-driven approach has identified novel BAP1-dependent adaptations in UM, by exploiting multi-omics data from an isogenic BAP1-mutated MPM model and correlating these with UM transcriptomic data. This may allow selection of effective drugs for BAP1 -mutant patients who are likely to develop mUM; UM cell line viability will initially be tested in response to drugs targeting FN1 (Ocriplasmin) and ATP1B1 (Digitoxin).
- Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo, BioSpecifics Technologies
[VIRTUAL] Identification of New Biomarkers and Therapeutic Targets in Gastric Cancer with Bioinformatic Analysis () - May 30, 2021 - Abstract #EACR2021EACR_341;
Moreover, Collagenase clostridium histolyticum, Halofuginone, and Ocriplasmin may have therapeutic potential in gastric cancer. Yet, these findings need to be confirmed by further experimental work.
- Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo, BioSpecifics Technologies
[VIRTUAL] Identification of New Biomarkers and Therapeutic Targets in Gastric Cancer with Bioinformatic Analysis () - May 30, 2021 - Abstract #EACR2021EACR_340;
Moreover, Collagenase clostridium histolyticum, Halofuginone, and Ocriplasmin may have therapeutic potential in gastric cancer. Yet, these findings need to be confirmed by further experimental work.
- Jetrea (ocriplasmin) / Oxurion, Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo, BioSpecifics Technologies
[VIRTUAL] Identification of New Biomarkers and Therapeutic Targets in Gastric Cancer with Bioinformatic Analysis () - May 30, 2021 - Abstract #EACR2021EACR_339;
Moreover, Collagenase clostridium histolyticum, Halofuginone, and Ocriplasmin may have therapeutic potential in gastric cancer. Yet, these findings need to be confirmed by further experimental work.